Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
International Journal of Radiation Oncology, Biology, Physics|September 24, 2017
Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate CancerMiguel Reis Ferreira, Atia Khan, Karen Thomas, et al.International Journal of Radiation Oncology, Biology, Physics|December 9, 2019
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: Efficacy and Toxicity in the DELINEATE TrialJulia R Murray, Alison C Tree, Emma J Alexander, et al.European Urology|August 31, 2024
Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047)Chris C Parker, Noel W Clarke, Adrian D Cook, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2019
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate CancerJames L Gulley, Michael Borre, Nicholas J Vogelzang, et al.European Urology|July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trialGerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.The Journal of Clinical Investigation|March 31, 2026
Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancerLarissa Mendes, Peter F Dutey-Magni, Emily Grist, et al.BJU International|January 17, 2013
Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohortChee L Goh, Edward J Saunders, Daniel A Leongamornlert, et al.Lancet (London, England)|May 19, 2024
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trialChris C Parker, Howard Kynaston, Adrian D Cook, et al.Lancet (London, England)|May 19, 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialChris C Parker, Noel W Clarke, Adrian D Cook, et al.Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.Pageof 3